Company profile
Verano Holdings Corp
OTC: VRNO · Healthcare · Drug Manufacturers - Specialty & Generic
#169 of 1,418 Healthcare companies by revenue35th-percentile growth
EA Score
59CFH 66DQ —GM 38SS 63
v0.1 · 45/100 weight · provisional
↑ workforce scale, operating margin · ↓ listing tenure, revenue growth (YoY)
Methodology →Revenue TTM
$817.9M
Rev growth YoY (TTM)
-5.7%
Net income (FY)
-$262.4M
Employees
3,800
as of 2026-08-12
Market cap
$432.4M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$835.9M$835.9M2025
Net income-$262.4M-$262.4M2025
Operating income$77.5M$77.5M2025
Total assets$1.8B$1.8B2025
Liabilities$1.1B$1.1B2025
Equity$702.9M$702.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Retail68%
Wholesale32%
By geography
Wholesale100%
The read
What is Verano Holdings Corp’s revenue?
Verano Holdings Corp booked $835.9M in FY2025 revenue, contracting 4.9% year over year — slower than 65% of Healthcare companies we track, at a -31.4% net margin.
Peers · Healthcare
Harmony Biosciences Holdings, Inc.76B+Innovage Holding Corp.68BVarex Imaging Corporation67BArrowhead Pharmaceuticals, Inc.76B+Myriad Genetics, Inc.67BOrthofix Medical Inc.75B+Neighbors
Cook →Key facts
CEOGeorge Archos
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersChicago, IL
ExchangeOTC: VRNO
Employees3,800
IPO date2021-02-17
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.